Oncolytic Adenovirus Global Market Report 2025

The oncolytic adenovirus market size has grown strongly in recent years. It will grow from $122.31 billion in 2024 to $132.87 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth during the historic period can be attributed to the rising prevalence of cancer, increasing demand for targeted cancer therapies, growing R&D funding, advancements in delivery methods, and regulatory approvals.

The oncolytic adenovirus market size is expected to see strong growth in the next few years. It will grow to $183.22 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to the rising prevalence and incidence of cancer, the expansion of combination therapies, regulatory advancements and approvals, technological progress in virus engineering, and increased investment in oncology research. Key trends include advancements in viral engineering techniques, innovative drug delivery systems, improved tumor-targeting precision, advanced immunotherapy combinations, and enhanced patient monitoring and diagnostics.

The rising incidence of cancer is expected to drive the expansion of the oncolytic adenovirus market in the coming years. Cancer is a disease characterized by uncontrolled cell growth and its spread to other parts of the body. Factors such as aging populations, lifestyle choices, environmental exposures, genetic predispositions, and advancements in detection contribute to the increasing number of cancer cases. Oncolytic adenoviruses selectively target and destroy cancer cells, presenting a promising therapeutic approach to addressing this growing health challenge. For example, in May 2024, the National Cancer Institute (NCI), a US-based government agency, reported nearly 20 million new cancer cases and 9.7 million deaths worldwide, with projections for 2040 rising to 29.9 million cases and 15.3 million deaths. Additionally, in 2023, the Australian Bureau of Statistics, an Australia-based government agency, reported that 1.8% of Australians had cancer, with males (2.1%) being slightly more affected than females (1.6%), particularly among those aged 75 and older. As a result, the increasing incidence of cancer is fueling growth in the oncolytic adenovirus market.

Companies operating in the oncolytic adenovirus market are focusing on combination therapies such as VCN-01, which integrates oncolytic virotherapy with chemotherapy to enhance tumor targeting and improve therapeutic outcomes. VCN-01 is an oncolytic adenovirus engineered to selectively infect and destroy cancer cells while also increasing the efficacy of chemotherapy. For instance, in May 2024, Theriva Biologics, a US-based clinical-stage immuno-oncology company, announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track Designation (FTD) to its lead candidate, VCN-01. This designation applies to VCN-01 in combination with gemcitabine and nab-paclitaxel for treating metastatic pancreatic adenocarcinoma. The oncolytic adenovirus VCN-01 replicates within tumor cells, helping to break down the tumor stroma, a significant barrier to effective cancer treatment.

In March 2022, Synthetic Biologics, Inc., a US-based biotechnology company, acquired VCN Biosciences for an undisclosed sum. This acquisition strengthens its drug development pipeline by incorporating VCN’s clinical-stage drug VCN-01 and preclinical candidate VCN-11, both of which are oncolytic adenoviruses designed to target cancers with high unmet medical needs. VCN Biosciences, S.L. (VCN) is a Spain-based biotechnology company specializing in the development of oncolytic adenoviruses for cancer treatment.

Major players in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, and SillaJen Inc.

North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oncolytic adenovirus report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oncolytic adenovirus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Oncolytic adenovirus is a genetically modified virus designed to selectively target and destroy cancer cells while preserving healthy tissue. It replicates within tumor cells, causing them to rupture and release new viral particles, which continue attacking the cancer. Additionally, it stimulates the immune system, enhancing the body's anti-tumor response.

The primary types of oncolytic adenoviruses include adenovirus type 5-based oncolytic viruses, adenovirus type 2-based oncolytic viruses, and other variants. Adenovirus type 5-based oncolytic viruses are genetically engineered to selectively infect and destroy cancer cells while sparing normal tissues. These viruses are used in the treatment of melanoma, prostate cancer, breast cancer, ovarian cancer, lung cancer, and other malignancies. End-users include hospitals, cancer research institutes, biotechnology companies, and academic and research institutions.

The oncolytic adenovirus market research report is one of a series of new reports that provides oncolytic adenovirus market statistics, including the oncolytic adenovirus industry global market size, regional shares, competitors with the oncolytic adenovirus market share, detailed oncolytic adenovirus market segments, market trends, and opportunities, and any further data you may need to thrive in the oncolytic adenovirus industry. This oncolytic adenovirus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oncolytic adenovirus market consists of revenues earned by entities by providing services such as virus engineering and customization, clinical trial management, regulatory consulting, and contract research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncolytic adenovirus market also includes sales of therapies, customized viral vectors, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.